Randomised double-blind comparison of placebo and active drugs for effects on risks associated with blood pressure variability in the Systolic Hypertension in Europe trial.

In multivariable-adjusted analyses ( table 3 ), VIM was not associated with the risk of any endpoint (p≥0.058), except for a borderline significant but inverse association with the risk of cardiac endpoints in a model not including SBP (p = 0.047).

also in 11,409 other papers